Calendario›LTGO›LTG-321

LTG-321

Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

Ensayo de Latigo Biotherapeutics, Inc. en Voluntarios sanos.

Fase

Fase 1

Estado

Completado

Participantes

112

previstos

Centros

1

Fin del objetivo primario

mar 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en sep 2025.

Qué mide

To evaluate the Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs) of single and multiple ascending oral doses of LTG-321 in healthy participants (Up to 14 days of dosing) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered LTG-321 in healthy male and female participants 18 to 55 years of age. The study will be conducted in New Zealand. The study also includes a randomized, double-blind, placebo-controlled, within-participant crossover evaluation of pain tolerance using a cold pressor test in healthy male participants 18 to 55 years of age. In addition, a randomized, open-label, crossover Food Effect cohort will evaluate the impact of a high-fat meal on the pharmacokinetics of LTG-321 following single oral doses in the fed and fasted state.

Más ensayos de LTGO

Todos los de LTGO, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07110610), actualizada en jun 2026.